QuickView for cellular response to purine-containing compound (biogroup)

1. L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
2. L1000 CMAP - Cervical cancer HELA.311 cells with CRISPR induced gene knockouts
3. L1000 CMAP - Kidney epithelial HA1E.101 cells with CRISPR targeted gene knockouts
4. L1000 CMAP - Neural progenitor NPC cells treated with small molecule perturbagens
5. L1000 CMAP - Hepatocellular carcinoma HEPG2 cells treated with small molecule perturbagens

There were no matches for cellular response to purine-containing compound

1. Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell…
2. B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid…
3. Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents…
4. TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatu…